• Lawsuit: Abbott FreeStyle Libre 3 glucose sensor defect class action
• Allegations: Sensors reportedly provide falsely low glucose readings despite known defect
• Products: FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors
• Status: Recently filed class action lawsuit

Abbott Glucose Sensor Class Action Alleges Defect Causes False Low Readings

A new class action lawsuit claims Abbott knowingly sold FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors with a defect that causes them to report falsely low glucose readings. According to a recent class action filing, the lawsuit alleges Abbott was aware of the defect but continued selling the affected sensors to consumers.

The complaint centers on Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems, which are widely used by people with diabetes to track their blood sugar levels without traditional finger-stick testing. The lawsuit alleges that the sensors' defect could potentially lead users to make incorrect medical decisions based on inaccurate readings.

What the Lawsuit Claims

The class action alleges that Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors contain a manufacturing or design defect that causes them to display glucose readings that are lower than a user's actual blood glucose levels. According to the complaint, this defect affects the sensors' ability to provide accurate glucose monitoring, which is critical for diabetes management.

The lawsuit claims Abbott knew about the defect but continued to market and sell the affected sensors without adequately warning consumers about the potential for inaccurate readings. The complaint alleges this constitutes a breach of warranty and violates consumer protection laws.

For people managing diabetes, accurate glucose readings are essential for making decisions about insulin dosing, food intake, and other medical interventions. The lawsuit suggests that falsely low readings could lead users to take actions that might not be appropriate for their actual glucose levels.

About FreeStyle Libre Sensors

Abbott's FreeStyle Libre systems use small sensors that are applied to the skin, typically on the upper arm, to continuously monitor glucose levels in tissue fluid. The sensors are designed to provide readings for up to 14 days without requiring traditional blood glucose meter testing.

The FreeStyle Libre 3 is Abbott's newest generation of the technology, featuring real-time glucose readings and smartphone connectivity. The system has gained popularity among diabetes patients as an alternative to more frequent finger-stick blood testing.

Legal Claims

The class action lawsuit appears to include claims for:

• Breach of express and implied warranties
• Violations of consumer protection statutes
• Unjust enrichment
• Negligent misrepresentation

The complaint seeks damages for consumers who purchased the allegedly defective sensors, though specific monetary amounts have not been disclosed. Class members may potentially seek refunds for the cost of the sensors or replacement devices.

Impact on Users

Glucose monitoring is a critical component of diabetes management, and inaccurate readings could potentially affect treatment decisions. The lawsuit alleges that users who relied on the sensors' readings may have received false information about their glucose levels.

However, medical professionals typically recommend that users of continuous glucose monitors confirm readings with traditional blood glucose meters when making treatment decisions, particularly for insulin dosing.

Next Steps in the Case

The class action is in its early stages, and Abbott has not yet publicly responded to the allegations in the lawsuit. The case will likely go through the typical class action process, including potential motions to dismiss, discovery, and class certification proceedings.

If the case moves forward, consumers who purchased the allegedly affected FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensors may potentially be eligible to participate in the class action. However, specific eligibility requirements and time periods have not yet been established.

The lawsuit represents another challenge for medical device manufacturers regarding the accuracy and reliability of consumer health monitoring products. As these devices become more prevalent, legal scrutiny of their performance and marketing claims may continue to increase.

Key Takeaways

• The lawsuit targets Abbott's newer FreeStyle Libre 3 sensor models, not earlier versions
• Allegations focus on falsely low readings rather than high readings
• The case is still in early litigation stages with no resolution timeline
• Users should continue following their healthcare provider's guidance for glucose monitoring

Anyone who has concerns about their FreeStyle Libre sensor readings should consult with their healthcare provider about proper glucose monitoring protocols.